Report period | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
---|---|---|---|---|---|---|
End date of the reporting period | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Capitalization, € | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Capitalization, $ | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Enterprise Value | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Book Value | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Shareholders Book Value | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Current liabilities | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Noncurrent liabilities | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Total liabilities | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Debt | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Cash and cash equivalents | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Net debt | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Assets | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Total ordinary shares | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Ordinary share price | ![]() | ![]() | ![]() | ![]() | ![]() | ![]() |
Date | Type | Note | Source |
---|---|---|---|
25.04.2025 10:00 | Dividends | The last day of purchase for receiving dividends €0.11 per common share for 2024. | ![]() |
30.04.2025 10:00 | Dividends | The company will pay dividends of €0.11 per common share for 2024. | ![]() |
Company name | Bayer |
---|---|
Tags | #pharmacy, #dax index |
Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Pharmaceuticals / Pharmaceuticals |
Business address | 51368 Leverkusen Germany |
Website | www.bayer.com |